Laura Fernández Landó

7PUBLICATIONS
18CO-AUTHORS
Aboriginal and Torres Strait Islander theory of change models for healthEpigenetics (incl. genome methylation and epigenomics)Gene and molecular therapyPredictive and prognostic markersPharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 15, 2024
Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6).

Kristina Secnik Boye, Jiat Ling Poon, Laura Fernández Landó

|Mar 26, 2024
Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes.

Bertrand Cariou, Jennifer Linge, Ian J Neeland

|Oct 26, 2023
Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS-1 monotherapy trial.

Julio Rosenstock, Clare J Lee, Laura Fernández Landó

|May 29, 2023
Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme.

Sue D Pedersen, Francesco Giorgino, Guillermo Umpierrez

|Mar 31, 2023
Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3.

Adie Viljoen, Kevin M Pantalone, Rodolfo J Galindo

|Feb 14, 2019
Relative contribution of basal and postprandial hyperglycaemia stratified by HbA1c categories before and after treatment intensification with dulaglutide.

Guillermo Umpierrez, Kevin M Pantalone, Charles M Atisso

Pageof 2

Frequent Collaborators

3 joint publications

Kevin M Pantalone

3 joint publications

Hiren Patel

2 joint publications

Guillermo Umpierrez

2 joint publications

Ruth Huh